CLINICAL EXPERIENCE WITH A NEW ANTITHYROID DRUG: 2-CARBETH0XYTHI0-1-METHYLGLYOX ALINE*†

Abstract

Clinical experience with a new drug, Neomercazole (C.G.I.) which has a structural formula similar to Tapazole (methimazole) with the H-atom replaced by a carbethoxy group, indicates that it is a potent antithyroid agent. The dose of Neomercazole required for effective antithyroid action is 30-50 mg. daily. Side effects of Neomercazole simulate those of Tapazole with reactions in 3 of 52 patients. Of 2 skin reactions, 1 was very severe; the other slight. In the 3d case, agranulocytosis developed on the 24th day of treatment; recovery followed the withdrawal of the drug and the admn. of antibiotics.